Economic Value of Dupilumab and Advanced Therapeutics in Patients With Type 2 Inflammatory Diseases in Italy: An Estimation of Healthcare Resource Utilization Cost Offsets
Author(s)
Furneri G1, Tavi J2, Joulain F2, Bego Le Bagousse G2, Dreyfus L3, Wang Z4, Kuznik A5, Dobreva M6, Fourrier L7, Cheng WH8
1PharmaLex S.p.A., Milan, Italy, 2Sanofi, Gentilly, Paris, France, 3Aixial Group, Boulogne-Billancourt, Paris, France, 4Regeneron Pharmaceuticals, Inc., Sleepy Hollow, NY, USA, 5Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA, 6Sanofi, Milan, Italy, 7Sanofi S.p.A., Milan, Italy, 8Sanofi, Cambridge, MA, USA
Presentation Documents
OBJECTIVES: To estimate cost offsets from the reductions in healthcare resource utilization (HCRU) due to an increased use of advanced therapeutics (ADTHs), including dupilumab in patients with atopic dermatitis (AD), asthma, and chronic rhinosinusitis with nasal polyps (CRSwNP) in Italy, using a budget-impact model from the National Health Services perspective over a 1-year time horizon.
METHODS: The model evaluated changes in HCRU at varying uptake levels of dupilumab and other ADTHs in AD (≥6 years), asthma (≥12 years), and CRSwNP (≥18 years). The ADTH-eligible patients were estimated using Italian epidemiology data (AD: N=22,235; asthma: N=16,065; CRSwNP: N=13,444). Clinical inputs were based on efficacy outcomes (AD: Eczema Area and Severity Index-75 at 16 weeks; asthma: annualized exacerbation rate; CRSwNP: nasal polyp score improvement ≥1 at 24 weeks) from published indirect treatment comparisons between dupilumab and other ADTHs. HCRU costs (2022 Italian euros) were assumed to include hospitalization, outpatient and emergency room visits associated with the disease management and asthma exacerbations. Three hypothetical scenarios were analyzed: (i) the current market with 2024 market shares; (ii) assuming a 5% increase in dupilumab uptake; and (iii) assuming a 5% increase in the uptake of all ADTHs proportionally based on their market shares. The increases were assumed from eligible patients currently receiving the best supportive care treatment.
RESULTS: Increasing the uptake of dupilumab by 5% is estimated to generate cost offsets of €4,954,000 compared with the current market (€226.35M vs. €231.30M) and of €288,200 compared with a proportional increase in ADTHs (€226.35M vs. €226.64M) as derived from the reductions in HCRU across all three diseases.
CONCLUSIONS: Our model indicates that the increased use of ADTH leads to substantial cost offsets across AD, asthma, and CRSwNP in Italy. These expected offsets are larger if the increased use is restricted to dupilumab only, given its efficacy across all three conditions.
Conference/Value in Health Info
Value in Health, Volume 27, Issue 12, S2 (December 2024)
Code
EE738
Topic
Economic Evaluation, Health Policy & Regulatory, Methodological & Statistical Research
Topic Subcategory
Budget Impact Analysis, Public Spending & National Health Expenditures
Disease
Biologics & Biosimilars, Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory)